Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 125

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 125
---
 candidates that are safer and more effective
than competing products.

Inflation

Inflation affects us by generally
increasing our cost of labor and research and development costs, the way it does to all labor and research costs. However, we do not anticipate
that inflation will materially affect our business in the foreseeable future.

Seasonality

We believe our operation and
sales do not experience seasonality.

Employees

As of the date of this annual
report, we have 1 full-time employees. Of these, 1 full-time are engaged in general and administrative functions. As of the date of this
annual report, all of our employees are located in Asia. In addition, we have engaged and may continue to engage 5 independent contracted
consultants and advisors to assist us with our operations. None of our employees are represented by a labor union or covered by a collective
bargaining agreement. We have never experienced any employment related work stoppages, and we consider our relations with our employees
to be good.

Intellectual Property

The technologies underlying
our various research and development projects are the subject of various patents and patent applications claiming, in certain instances,
composition of matter and, in other instances, methods of use. Prosecution, maintenance and enforcement of these patents, as well as those
on any future protectable technologies we may acquire, are and will continue to be an important part of our strategy to develop and commercialize
novel medicines, as described in more detail below. Through entering into license agreements with their owners, we have obtained exclusive
rights to these patents, applications and related know-how in the U. S. and certain other countries to develop, manufacture and commercialize
the products using or incorporating the protected inventions that are described in this annual report and that are expected to contribute
significant value to our business. The technologies protected by these patents may also for the basis for the development of other products.

In addition to licensed intellectual
property, our in-house science team has been actively developing our own proprietary intellectual property. No non-provisional patent
application has yet been filed in the Company’s own name for the Lead Projects. We have, however, filed a number of provisional
applications to establish earlier filing dates for certain of our other ongoing researches, the specifics of which are currently proprietary
and confidential.

The U. S. patent system permits
the filing of provisional and non-provisional patent applications (i. e., a regular patent application). A non-provisional patent application
is